This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fisher, B. Articles by Gunduz, N. Search for Related Content PubMed PubMed Citation Articles by Fisher, B. Articles by Gunduz, N.

Effect of Local or Systemic Treatment Prior to Primary Tumor Removal on the Production and Response to a Serum Growth-stimulating Factor in Mice¹

University of Pittsburgh, Pittsburgh, Pennsylvania 15261

This report indicates that not only does the preoperative administration of cyclophosphamide or radiation prevent the kinetic changes observed in a distant tumor focus following tumor removal but that the preoperative administration of the antiestrogen tamoxifen and the luteinizing hormone-releasing hormone analogue Zoladex are equally effective in that regard. It also provides evidence indicating that serum obtained from mice treated with those therapies when transferred to a recipient bearing a tumor of a similar type to that in the donor fails to stimulate DNA synthesis in the tumor of the recipient. In contrast, an increase in labeling index occurs following transfer of serum obtained following tumor removal from untreated mice. Moreover, when tumor-bearing mice were treated by each of the four modalities prior to receiving serum obtained from untreated donors following removal of a tumor, no kinetic changes were observed in the tumor of the serum recipient.

¹ This investigation was supported in part by USPHS Grant RO1-CA-14972 awarded by the National Cancer Institute, Department of Health and Human Services.

² To whom requests for reprints should be addressed, at Room 914, Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261.

Received 8/15/88. Revised 12/21/88. Accepted 1/13/89.

This article has been cited by other articles:

				L. Gianni, J. Baselga, W. Eiermann, V. Guillem Porta, V. Semiglazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. Llombart Cussac, et al. Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy Clin. Cancer Res., December 15, 2005; 11(24): 8715 - 8721. [Abstract] [Full Text] [PDF]

				D. Mauri, N. Pavlidis, and J. P. A. Ioannidis Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis J Natl Cancer Inst, February 2, 2005; 97(3): 188 - 194. [Abstract] [Full Text] [PDF]

				S. J. Cleator, A. Makris, S. E. Ashley, R. Lal, and T. J. Powles Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival Ann. Onc., February 1, 2005; 16(2): 267 - 272. [Abstract] [Full Text] [PDF]

				A. M. Chen, F. Meric-Bernstam, K. K. Hunt, H. D. Thames, M. J. Oswald, E. D. Outlaw, E. A. Strom, M. D. McNeese, H. M. Kuerer, M. I. Ross, et al. Breast Conservation After Neoadjuvant Chemotherapy: The M.D. Anderson Cancer Center Experience J. Clin. Oncol., June 15, 2004; 22(12): 2303 - 2312. [Abstract] [Full Text] [PDF]

				G. Ganem, M. Tubiana-Hulin, P. Fumoleau, M. Combe, J.-L. Misset, J.-M. Vannetzel, T. Bachelot, L. R. De Ybarlucea, V. Lotz, B. Bendahmane, et al. Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer Ann. Onc., November 1, 2003; 14(11): 1623 - 1628. [Abstract] [Full Text] [PDF]

				C. Shannon, S. Ashley, and I.E. Smith Does Timing of Adjuvant Chemotherapy for Early Breast Cancer Influence Survival? J. Clin. Oncol., October 15, 2003; 21(20): 3792 - 3797. [Abstract] [Full Text] [PDF]

				M. Dowsett Preoperative Models to Evaluate Endocrine Strategies for Breast Cancer Clin. Cancer Res., January 1, 2003; 9(1): 502S - 510S. [Abstract] [Full Text] [PDF]

				A. C. Wolff and N. E. Davidson Preoperative Therapy in Breast Cancer: Lessons from the Treatment of Locally Advanced Disease Oncologist, June 1, 2002; 7(3): 239 - 245. [Abstract] [Full Text] [PDF]

				R. R. Love, N. B. Duc, N. V. Dinh, T.-Z. Shen, T. C. Havighurst, D. C. Allred, and D. L. DeMets Mastectomy and Oophorectomy by Menstrual Cycle Phase in Women With Operable Breast Cancer J Natl Cancer Inst, May 1, 2002; 94(9): 662 - 669. [Abstract] [Full Text] [PDF]

				J. A. van der Hage, C. J.H. van de Velde, J.-P. Julien, M. Tubiana-Hulin, C. Vandervelden, and L. Duchateau Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902 J. Clin. Oncol., November 15, 2001; 19(22): 4224 - 4237. [Abstract] [Full Text]

				J. Song and P. W. Melera Transmembrane Domain (TM) 9 Represents a Novel Site in P-Glycoprotein That Affects Drug Resistance and Cooperates with TM6 to Mediate [125I]Iodoarylazidoprazosin Labeling Mol. Pharmacol., August 1, 2001; 60(2): 254 - 261. [Abstract] [Full Text] [PDF]

				A. C. Wolff and N. E. Davidson Primary Systemic Therapy in Operable Breast Cancer J. Clin. Oncol., April 7, 2000; 18(7): 1558 - 1569. [Abstract] [Full Text] [PDF]

				K. D. Miller, W. McCaskill-Stevens, J. Sisk, D. M. Loesch, F. Monaco, R. Seshadri, and G. W. Sledge Jr Combination Versus Sequential Doxorubicin and Docetaxel as Primary Chemotherapy for Breast Cancer: A Randomized Pilot Trial of the Hoosier Oncology Group J. Clin. Oncol., October 1, 1999; 17(10): 3033 - 3037. [Abstract] [Full Text] [PDF]

				J.R. Siewert, H.J. Stein, and U. Fink Multimodality Therapy for Esophageal Cancer Oncologist, August 1, 1996; 1(4): 210 - 218. [Abstract] [Full Text] [PDF]